Status:
COMPLETED
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
Lead Sponsor:
Abbott
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receiv...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Stage IIIB or IV non-small cell lung cancer.
- Recurrent tumor following treatment with paclitaxel or docetaxel.
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney and liver function.
- Exclusion Criteria
- Pregnant or breast feeding.
- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
- CNS metastasis.
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00073151
Start Date
September 1 2003
End Date
January 1 2006
Last Update
November 29 2007
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Hematology Group of South Florida
Miami, Florida, United States
2
Florida Cancer Institute
New Port Richey, Florida, United States
3
University of Chicago Medical Center
Chicago, Illinois, United States, 60637-1460
4
University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States, 21201-1595